Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key ...
Alvotech S.A. (NASDAQ: ALVO) is focused solely on biosimilars—biologic medicines designed to be highly similar to already-approved reference products. The company operates with the goal of improving patient outcomes while expanding access to effective therapies in a more sustainable way for healthcare systems. Alvotech’s platform combines development capabilities with in-house/partner ...Alvotech S.A. (NASDAQ: ALVO) is focused solely on biosimilars—biologic medicines designed to be highly similar to already-approved reference products. The company operates with the goal of improving patient outcomes while expanding access to effective therapies in a more sustainable way for healthcare systems. Alvotech’s platform combines development capabilities with in-house/partner manufacturing execution across multiple therapeutic areas, emphasizing lifecycle management and scale for global commercialization.
Business model and service offering: Alvotech’s core “product” is the biosimilar itself, but its work spans the end-to-end value chain—biosimilar development, manufacturing, and regulatory readiness to support launches in different markets. This includes clinical development planning, manufacturing process development and control, and ongoing pipeline activities to bring additional biosimilar candidates forward.
Key products and pipeline: The supplied information highlights several flagship programs. AVT02 is a high-concentration biosimilar equivalent to Humira, intended for inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. AVT04 is developed as a biosimilar to Stelara, targeting similar inflammatory conditions including psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. For ophthalmology, AVT06 is a biosimilar to Eylea, aimed at diseases such as age-related macular degeneration, macular edema, and diabetic retinopathy. The company also references earlier-stage work such as AVT03 (biosimilar to Xgeva/Prolia) for oncology- and bone-related indications, and AVT05 (early-stage biosimilar for Simponi/Simponi Aria) across inflammatory indications. Additional candidates mentioned include AVT16 (immunology), AVT23 (late-stage biosimilar to Xolair for nasal polyps), and AVT33 (oncology).
Cost and BOM considerations (biosimilar context): While biosimilars are biologics rather than traditional small-molecule generics, the economics still often depend on reducing unit costs through manufacturing scale, optimizing yields, and leveraging platform know-how across multiple programs. In practice, cost structure is influenced by development and clinical expenses, manufacturing capacity and process validation, regulatory activities, and supply-chain consistency for biologic raw materials and biologic production inputs.
Financial/perspective signals: Public-market metrics provided in the source suggest the company operates in a capital-intensive biotech cycle typical of biosimilar developers, with pipeline progression rather than near-term profitability being a key driver. Investor focus is commonly on program timelines, regulatory outcomes, launch execution, and manufacturing/quality scale readiness.
Key people: Róbert Wessman is identified as the founder of Alvotech (founded in 2013). The dataset also lists Lisa Graver as CEO. This combination reflects both founding leadership history and current executive management.
Wishes/aspirations and mission: Alvotech frames its mission around improving patient lives and supporting the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilar medicines.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$586.3M
+19.7%
-0.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$27.9M
+112.0%
-6587.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+59.8%
-3.8%
-10.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+13.3%
-6.2%
-223.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+4.8%
+110.1%
-6593.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-114.7M
+61.0%
+55.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-19.6%
+67.4%
+55.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-509.4%
-76.7%
-46.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.89x
-19.8%
-6.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, and thank you for standing by. Welcome to the Alvotech Q2 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Benedikt Stefansson, VP of Investor Relations and Global Communications. Please go ahead.
Benedikt Stefansson: Thank you, and welcome to our listeners. Yesterday evening, the company issued a press release announcing our financial results for the first half of 2026. Material accompanying today's earnings call, including a supplemental earnings report, providing additional operational details and a business update and the presentation we will be referring to on today's call were also published on our website, alvotech.com, under Financials in the Q2 section. Our press release, earnings report, presentation and statements that we make on the call today may include forward-looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission. Any risks and uncertainties could cause actual results to differ materially from forward-looking statements that are made. Presenting on today's call are Róbert Wessman, Founder and Executive Chairman; Lisa Graver, Chief Executive Officer; Joseph McClellan, Chief Operating Officer; and Linda Jonsdottir, Chief Financial Officer. Róbert will begin today's presentation with a summary of our regulatory, funding and commercial highlights. Lisa will then present a commercial and operations update. Joseph will provide a pipeline and regulatory update, and Linda will conclude with a discussion of the financial results. Following the presentation, our team will be happy to take your questions. And with that, I would like to turn the call over to Róbert Wessman.
Robert Wessman: Hello, everyone, and thank you for joining us here today. The first half has been an important period for Alvotech as we made the significant investments in our manufacturing facility and quality systems. These investments allowed us to resubmit our US BLAs in June. And in July, the FDA formally closed the May surveillance inspection of our [ Alvotech ] facility with a VAI classification. Our second quarter performance reflects the associated production slowdown and the preparation for our BLA resubmissions. Manufacturing returned to planned operating levels at the end of the second quarter. Our order book is strong, which will support a strong fourth quarter as we seek to gradually rebuild sufficient safety stock for our customers. During the period, we also continued to expand our commercial portfolio, make significant progress in our R&D programs and strengthen our financial position to support the next phase of growth. We are optimistic about our first-mover position with our ENTYVIO biosimilar program. We were the first to submit a BLA in the U.S., and we have …
